

10 Postinterventionelles Prozedere

10.1 Medikamentöse Therapie nach HKU

- [1] Zhang ZJ, Marroquin OC, Weissfeld JL et al. Beneficial effects of statins after percutaneous coronary intervention. *Europ J Cardiovasc Prev Rehab* 16:445–450, 2009
- [2] Jastrow H, Weber AA. Grundlagen der Thrombozytenpharmakologie. *Pharmakologie in unserer Zeit* 38:302–304, 2009
- [3] Valgimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 39:213–260, 2018
- [4] Valgimigli M, Costa F, Byrne R et al. Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. *EuroIntervention* 11:68–74, 2015
- [5] Yeh RW, Secemsky EA, Kereiakes DJ et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. *JAMA* 315:1735–1749, 2016
- [6] Costa F, van Klaveren D, James S et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. *Lancet* 389:1025–1034, 2017
- [7] Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 361:1045–1057, 2009
- [8] Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 357:2001–2015, 2007
- [9] Agewall S, Cattaneo M, Collet JP et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. *Eur Heart J* 34:1708–1713, 2013
- [10] Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. *N Engl J Med* 363:1909–1917, 2010
- [11] Gargiulo G, Costa F. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. *Am Heart J* 174: 95–102, 2016
- [12] Moukarbel GV, Bhatt DL. Antiplatelet therapy and proton pump inhibition: clinician update. *Circulation* 125:375–380, 2012
- [13] Fortuna LA, Pawloski PA, Parker ED et al. Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events. *Eur Heart J Cardiovasc Pharmacother* 2:13–19, 2016
- [14] Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 324:71–86, 2002
- [15] Rothwell PM, Cook NR, Gaziano JM et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. *Lancet* 392:387–399, 2018
- [16] Theken KN, Grosser T. Weight-adjusted aspirin for cardiovascular prevention. *Lancet* 392:361–362, 2018

- [17] Mehta SR, Tanguay JF, Eikelboom JW et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. *Lancet* 376:1233–1243, 2010
- [18] Wiviott S, Braunwald E, McCabe CH et al., TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 357:2001–2015, 2007
- [19] Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 361:1045–1057, 2009
- [20] Schömig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. *N Engl J Med* 334:1084–1089, 1996
- [21] Silber S, Borggrefe M, Böhm M et al. Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamenten freisetzen-den Koronarstents (DES). Eine evidenzbasierte Analyse von 71 randomisierten Studien mit 28 984 Patienten. *Kardiologie* 1:84–111, 2007
- [22] Gwon HC, Hahn JY, Park KW et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. *Circulation* 125:505–513, 2012
- [23] Valgimigli M, Campo G, Monti M et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. *Circulation* 125:2015–2026, 2012
- [24] Schulz-Schupke S, Byrne RA, Ten Berg JM et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. *Eur Heart J* 36:1252–1263, 2015
- [25] Han Y, Xu B, Xu K et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized sub-study of the I-LOVE-IT 2 trial. *Circ Cardio-vasc Interv* 9:e003145, 2016
- [26] Kim BK, Hong MK, Shin DH et al. A new strategy for discontinuation of dual anti-platelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual anti-platelet Therapy following Endeavor zotarolimus-eluting stent implantation). *J Am Coll Cardiol* 60:1340–1348, 2012
- [27] Feres F, Costa RA, Abizaid A et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. *JAMA* 310:2510–2522, 2013
- [28] Urban P, Meredith IT, Abizaid A et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. *N Engl J Med* 373:2038–2047, 2015
- [29] Valgimigli M, Patialiakas A, Thury A et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. *J Am Coll Cardiol* 65:805–815, 2015
- [30] Palmerini T, Benedetto U, Bacchi-Reggiani L et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. *Lancet* 385:2371–2382, 2015
- [31] Vranckx P, Valgimigli M, Jüni P et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. *Lancet* 392(10151):940–949, 2018
- [32] Costa F, Tijssen JG, Ariotti S et al. Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy. *J Am Heart Assoc* 2015
- [33] Costa F, van Klaveren D, James S et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. *Lancet* 389:1025–1034, 2017
- [34] Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent

- acute coronary syndrome. *N Engl J Med* 366:9–19, 2012
- [35] Eikelboom JW, Connolly SJ, Bosch J. Rivaroxaban with or without aspirin in stable cardiovascular disease. *N Engl J Med* 377: 1319–1330, 2017
- [36] Connolly SJ, Eikelboom JW, Bosch J et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. *Lancet* 391(10117):205–218, 2018
- [37] Hess CN, James S, Lopes RD et al. Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: Insights from the APPRAISE-2 Trial. *J Am Coll Cardiol* 66:777–787, 2015
- [38] Dewilde WJ, Oirbans T, Verheugt FW et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. *Lancet* 381(9872):1107–1115, 2013
- [39] Gibson CM, Mehran R, Bode C et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. *N Engl J Med* 375:2423–2434, 2016
- [40] Cannon CP, Bhatt DL, Oldgren J et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. *N Engl J Med* 377:1513–1524, 2017
- [41] Bonzel T, Erbel R, Hamm CW et al. Leitlinie Perkutane Koronarinterventionen (PCI). *Clin Res Cardiol* 28:513–547, 2008
- [42] Jolly SS, Faxon DP, Fox KAA et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines – results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. *J Am Coll Cardiol* 4:468–476, 2009
- [43] Valgimigli, M, Frigoli E, Leonardi S et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. *N Engl J Med* 373:997–1009, 2015
- [44] Bolognese L, Falsini G, Liistro F et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. *J Am Coll Cardiol* 47:522–528, 2006
- [45] Kandzari DE, Kirtane AJ, Windecker S et al., Onyx ONE US/Japan Investigators. One-month dual antiplatelet therapy following percutaneous coronary intervention with zotarolimus-eluting stents in high-bleeding-risk patients. *Circ Cardiovasc Interv* 13(11):e009565, 2020
- [46] Mehran R, Baber U, Steg PG et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. *Lancet* 382(9906):1714–1722, 2013
- [46a] Byrne RA, Rossello X, Coughlan JJ et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. *Eur Heart J* 44:3720–826. Erratum in: *Eur Heart J* 2024

10.2 Dokumentation und Befundung

- [1] Schächinger V, Nef H, Achenbach S et al. Leitlinie zum Einrichten und Betreiben von Herzkatheterlaboren und Hybridoperationssälen/Hybridlaboren, 3. Aufl. 2015. *Kardiologie* 9:89–123, 2015

10.3 Qualitätsmanagement im HKL

- [1] Erbel R, Sommerfeld U, Ashry M et al. Qualitätsmanagement im Herzkatheterlabor. *Z Kardiol* 83(Suppl 6):43–55, 1994
- [2] Kamiske GF, Brauer JP. Qualitätsmanagement von A bis Z. Hanser, München, Wien, 1993
- [3] Deming WE. Out of the crisis. 2. Aufl. Massachusetts Institute of Technology Press, Cambridge/MA, 1986
- [4] Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTiG). Qualitätsreport 2019. https://iqtig.org/downloads/berichte/2018/IQTiG_Qualitaetsreport-2019_2019-09-25.pdf (23.05.2020)